These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 16981822)
41. Beneficial effects of CD39/ecto-nucleoside triphosphate diphosphohydrolase-1 in murine intestinal ischemia-reperfusion injury. Guckelberger O; Sun XF; Sévigny J; Imai M; Kaczmarek E; Enjyoji K; Kruskal JB; Robson SC Thromb Haemost; 2004 Mar; 91(3):576-86. PubMed ID: 14983235 [TBL] [Abstract][Full Text] [Related]
42. Characterization of NTPDase (NTPDase1; ecto-apyrase; ecto-diphosphohydrolase; CD39; EC 3.6.1.5) activity in human lymphocytes. Leal DB; Streher CA; Neu TN; Bittencourt FP; Leal CA; da Silva JE; Morsch VM; Schetinger MR Biochim Biophys Acta; 2005 Jan; 1721(1-3):9-15. PubMed ID: 15652174 [TBL] [Abstract][Full Text] [Related]
43. Interview: A perspective on personalized medicine: Dr David Korn. Korn D Per Med; 2012 May; 9(3):259-263. PubMed ID: 29758794 [TBL] [Abstract][Full Text] [Related]
44. CD39+ regulatory T cells attenuate allergic airway inflammation. Li P; Gao Y; Cao J; Wang W; Chen Y; Zhang G; Robson SC; Wu Y; Yang J Clin Exp Allergy; 2015 Jun; 45(6):1126-37. PubMed ID: 25728362 [TBL] [Abstract][Full Text] [Related]
45. Protective role of hypoxia-inducible factor-1α-dependent CD39 and CD73 in fulminant acute liver failure. Tak E; Jung DH; Kim SH; Park GC; Jun DY; Lee J; Jung BH; Kirchner VA; Hwang S; Song GW; Lee SG Toxicol Appl Pharmacol; 2017 Jan; 314():72-81. PubMed ID: 27899277 [TBL] [Abstract][Full Text] [Related]
46. Therapeutic potentials of ecto-nucleoside triphosphate diphosphohydrolase, ecto-nucleotide pyrophosphatase/phosphodiesterase, ecto-5'-nucleotidase, and alkaline phosphatase inhibitors. al-Rashida M; Iqbal J Med Res Rev; 2014 Jul; 34(4):703-43. PubMed ID: 24115166 [TBL] [Abstract][Full Text] [Related]
51. Targeted deletion of ectonucleoside triphosphate diphosphohydrolase 1/CD39 leads to desensitization of pre- and postsynaptic purinergic P2 receptors. Schaefer U; Machida T; Broekman MJ; Marcus AJ; Levi R J Pharmacol Exp Ther; 2007 Sep; 322(3):1269-77. PubMed ID: 17565006 [TBL] [Abstract][Full Text] [Related]
52. Structural elements and limited proteolysis of CD39 influence ATP diphosphohydrolase activity. Schulte am Esch J; Sévigny J; Kaczmarek E; Siegel JB; Imai M; Koziak K; Beaudoin AR; Robson SC Biochemistry; 1999 Feb; 38(8):2248-58. PubMed ID: 10029517 [TBL] [Abstract][Full Text] [Related]
53. [Phenotypical and functional characteristic of FoxP3(+);CD39(+); regulatory T cells in humans]. Huang HH; Wang SY; Wang HF; Fu JL; Han P; Wang FS Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2010 Jun; 26(6):536-8. PubMed ID: 20487644 [TBL] [Abstract][Full Text] [Related]
54. Functional analysis of expression of human ecto-nucleoside triphosphate diphosphohydrolase-1 and/or ecto-5'-nucleotidase in pig endothelial cells. De Giorgi M; Pelikant-Malecka I; Sielicka A; Slominska EM; Giovannoni R; Cinti A; Cerrito MG; Lavitrano M; Smolenski RT Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):313-8. PubMed ID: 24940685 [TBL] [Abstract][Full Text] [Related]
55. Expression and characterization of human ecto-ATPase and chimeras with CD39 ecto-apyrase. Hicks-Berger CA; Kirley TL IUBMB Life; 2000 Jul; 50(1):43-50. PubMed ID: 11087120 [TBL] [Abstract][Full Text] [Related]
56. Its all about delivery: interview with M. N. V. Ravi Kumar. Kumar MN Ther Deliv; 2015; 6(10):1135-7. PubMed ID: 26446378 [TBL] [Abstract][Full Text] [Related]
57. Centenary of the Birth of Academician Prof. Dr. Isak Tadzer, Founder of the Pathophysiology and Nuclear Medicine in Macedonia. Karanfilski B Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2017 Sep; 38(2):9-17. PubMed ID: 28991760 [TBL] [Abstract][Full Text] [Related]
58. Regulated catalysis of extracellular nucleotides by vascular CD39/ENTPD1 is required for liver regeneration. Beldi G; Wu Y; Sun X; Imai M; Enjyoji K; Csizmadia E; Candinas D; Erb L; Robson SC Gastroenterology; 2008 Nov; 135(5):1751-60. PubMed ID: 18804472 [TBL] [Abstract][Full Text] [Related]
59. In vitro screening of drug metabolism during drug development: an interview with Olavi Pelkonen. Treadway A Expert Opin Drug Discov; 2006 Jun; 1(1):15-7. PubMed ID: 23506029 [TBL] [Abstract][Full Text] [Related]
60. Abass Alavi: A giant in Nuclear Medicine turns 80 and is still going strong! Høilund-Carlsen PF Hell J Nucl Med; 2018; 21(1):85-87. PubMed ID: 29550853 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]